Validation of RNA FISH to measure mRNA decay, related to Figure 1. Jurkat cells were cytospun onto coverslips and stained by RNA FISH according to the experimental methods. (A) FISH performed on untreated Jurkat cells confirmed the specificity of poly(A) and 18S FISH. Sodium hydroxide treatment, which hydrolyzes RNA, but not DNA, abolished mRNA and rRNA staining, but not DAPI staining. This strongly suggests that the FISH was specific for RNA. (B) Jurkat cells were treated with αFas for 3 hr in the presence of blebbistatin, an inhibitor of blebbing. Apoptosis was confirmed by annexin V staining (data not shown). mRNA still disappeared in non-blebbing αFas-treated cells undergoing apoptosis. The minority of cells with persistent poly(A) signal had DAPI staining that showed non-apoptotic nuclei. Scale bar represents 10 µm.
(A-C) HCT116 cells were treated with thapsigargin, or left untreated, for 12 hrs, then cells were harvested for annexin V staining (A) or RNA was harvested and the indicated mRNAs (B) or ncRNAs (C) were assayed by qRT-PCR. mRNAs consistently declined, while ncRNAs were more stable.
(D-F) HCT116 cells were treated with tunicamycin, or left untreated, for 12 hrs, then cells were harvested for annexin V staining (D) or RNA was harvested and the indicated mRNAs (E) or ncRNAs (F) were assayed by qRT-PCR. mRNAs consistently declined, while ncRNAs were more stable.
(G-J) The indicated reporters (G) were transfected into HeLa cells, 48 hr later the cells were treated with STS or left untreated. GFP RNA expression was analyzed by Northern blot (H). The Northern blot probe targeted the GFP coding region. All of the constructs produced GFP RNA when introduced into cells. GFP protein expression was assayed by immunoblot (I) and flow cytometry (J). There was high protein expression from transcripts driven by a polymerase II (Pol II) promoter. When the polyadenylation signal sequence (PAS) was replaced by a self-cleaving hammerhead ribozyme (HR), protein expression was lost, but rescued by the addition of 60 adenine or 60 uridine nucleotides before the HR sequence. (D-G) EEF1A mRNAs were amplified by cRACE with a forward primer in the ORF. PCR products were run on a gel (D) and the fragments were isolated by gel purification. Some EEF1A decay products with intact 5´ ends had nontemplated tails, which were rich in uridylates (E). As with the ACTB mRNA decay products, most clones derived from TAP-treated RNA had intact 5´ ends (F), while all clones from TAP-untreated RNA had evidence of 5´ to 3´ decay (G). Clones in E-G were all isolated in one experiment. (C,D) HeLa cells were transfected with CTL or DIS3L2 siRNAs, then treated with STS for 4 hr. Total RNA was harvested and subjected to U-tailing assays. U-tailed ACTB decay intermediates (arrow) accumulated in STS-treated HeLa cells after DIS3L2 knockdown as measured by RT-PCR (C) and cRACE (D). U-tailed intermediates also accumulated in untreated living cells after DIS3L2 knockdown (C). A summary of the cRACE results with statistical analysis is presented in Figure 7C .
(E-G) DIS3L2 knockdown in HeLa cells partially restored mRNA levels (E) and reduced effector caspase activation (F) and caspase 3 cleavage (G) following 4 hr of treatment with STS. Error bars represent SEM of at least 3 independent experiments. * p<0.05; **p<0.01.
RNA level after STS, relative to untreated and normalized to 7SL (log (H,I) HeLa cells were transfected with the indicated siRNA pools and RNA was analyzed by qRT-PCR relative to 7SL at the indicated times after adding α-amanitin+/-STS (H). The mRNA half-lives in STS-treated Hela cells were determined using the one-phase exponential decay equation (I). DIS3L2, but not DIS3L1, siRNAs increased mRNA half-life after STS treatment. (J-N). HCT116 cells were transfected with CTL, DIS3L1 or DIS3L2 siRNAs, then treated with TRAIL or left untreated for 3 hrs. Knockdown was confirmed by qRT-PCR (J), mRNA levels were measured by qRT-PCR relative to 7SL (K), apoptosis was assayed by annexin V staining (L), and caspase activation was measured by immunoblot (M) and a luminescent assay (N). DIS3L2, but not DIS3L1 siRNAs rescued mRNA levels, apoptosis, and caspase 3 cleavage and activation.
(O) HeLa cells were transfected with the indicated siRNA pools, then treated with the indicated dose of TRAIL and stained with annexin V. DIS3L2, but not DIS3L1, siRNAs reduced apoptosis in response to all of the different doses of TRAIL. Error bars represent SEM of at least 3 independent experiments. * p<0.05; **p<0.01; ***p<0.001. Table S1 . Taqman miRNA qRT-PCR was performed according to the manufacturer's instructions (Life Technologies N808-0234).
The following kits from Life Technologies were used for reverse transcription and qPCR.
miR-16: #000391, miR-21: #000397, U6: #001093.
Western blotting
Western blotting was performed as described previously (Rajani et al., 2012) . All primary antibodies were used at 1:1000 and secondary antibodies at 1:2500.
The following antibodies were used: ACTB (DSHB, #JLA20-c); PARP1 (Santa Cruz, H- BCL2L3 (MCL-1) (M-004501-08-0005). In Figure 7C and Figure S5A -G, the following siRNAs were used (from Ambion): CTL (4390843); DIS3L2 (s43418). In Figure 6 , the following siRNAs were used (from Ambion): CTL (4390843); ZCCHC6 (s36060); ZCCHC11 (s235511); PAPD7 (s21760). In Figure S5J -N, the following siRNAs were used (from Ambion): CTL (4390843); DIS3L1 (s41866); DIS3L2 (s43419). Table S1 . 
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